{"id":"gemcitabine-carboplatin-plus-iniparib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. Carboplatin is a platinum-based chemotherapeutic agent that forms platinum-DNA adducts, causing DNA damage and apoptosis. Iniparib, on the other hand, is a PARP inhibitor that blocks the repair of DNA damage, making cancer cells more susceptible to chemotherapy-induced cell death.","oneSentence":"Gemcitabine and carboplatin work by interfering with DNA replication and cell division, respectively, while iniparib is thought to work by inhibiting PARP enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:14.896Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced ovarian cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT00422682","phase":"PHASE1","title":"A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Tumors","enrollment":136},{"nctId":"NCT00813956","phase":"PHASE2","title":"A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-12","conditions":"Triple Negative Breast Cancer","enrollment":80},{"nctId":"NCT01033123","phase":"PHASE2","title":"A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-12","conditions":"Ovarian Cancer","enrollment":41},{"nctId":"NCT01082549","phase":"PHASE3","title":"Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Squamous Cell Lung Cancer","enrollment":780},{"nctId":"NCT01033292","phase":"PHASE2","title":"A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-12","conditions":"Ovarian Cancer","enrollment":43},{"nctId":"NCT01455532","phase":"PHASE1","title":"A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Neoplasm Malignant","enrollment":59},{"nctId":"NCT01045304","phase":"PHASE2","title":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Breast Cancer, Metastatic","enrollment":163},{"nctId":"NCT00938652","phase":"PHASE3","title":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Breast Cancer","enrollment":519},{"nctId":"NCT01130259","phase":"","title":"An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Sanofi","startDate":"","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01213381","phase":"PHASE1","title":"Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Advance Solid Tumors","enrollment":18},{"nctId":"NCT00540358","phase":"PHASE2","title":"A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Breast Cancer","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"gemcitabine/carboplatin plus Iniparib","genericName":"gemcitabine/carboplatin plus Iniparib","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine and carboplatin work by interfering with DNA replication and cell division, respectively, while iniparib is thought to work by inhibiting PARP enzymes. Used for Advanced ovarian cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}